Tirzepatide has reshaped the landscape of weight management and metabolic health since its arrival in U.S. clinics. As a dual GIP/GLP-1 receptor agonist, it targets two hormone pathways simultaneously – a mechanism that explains why clinical trials have shown it outperforming older single-agonist medications in head-to-head comparisons. In the SURMOUNT-5 trial, tirzepatide produced an average weight reduction of 20.2% (about 50 lbs) over 72 weeks, compared with 13.7% (about 33 lbs) for injectable semaglutide.
This guide covers the current FDA-approved tirzepatide dosing schedule, titration protocols, and the practical considerations that help patients and providers get the most out of treatment – all updated for 2026.
How tirzepatide works: the dual-agonist advantage for effective weight loss
Most GLP-1 medications work through a single hormonal pathway, stimulating glucagon-like peptide-1 receptors to slow gastric emptying, suppress appetite, and improve insulin sensitivity. Tirzepatide does all of that, and adds activation of glucose-dependent insulinotropic polypeptide (GIP) receptors.
GIP acts on energy balance through signaling in the brain and adipose tissue. Together, these two pathways produce more pronounced appetite suppression and metabolic effects than either hormone alone. This is part of why the dosing philosophy for tirzepatide – starting very low and escalating gradually – is so important: the medication is potent, and the body needs time to adapt.
Zepbound and Mounjaro brief dosing guides
Tirzepatide is available in the United States under two brand names, both manufactured by Eli Lilly:
- Mounjaro – FDA-approved to improve blood sugar control in adults with type 2 diabetes, used alongside diet and exercise
- Zepbound – FDA-approved for chronic weight management in adults with obesity, or adults who are overweight with at least one weight-related condition. As of 2024, Zepbound also carries an indication for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.
Both brands contain identical active ingredients and share the same dosing strengths and titration schedule. The distinction matters for insurance coverage and intended use, but not for the pharmacology of the drug itself. For patients pursuing weight loss, Zepbound is the appropriate FDA-approved vehicle.
| Mounjaro dosing | Zepbound dosing | |
| FDA Indication | Type 2 diabetes | Weight loss & sleep apnea |
| Active Ingredient | Tirzepatide | Tirzepatide |
| Starting Dose | 2.5 mg/week | 2.5 mg/week |
| Max Dose | 15 mg/week | 15 mg/week |
| Delivery | Single-dose pen | Single-dose pen or KwikPen |
| Self-pay (LillyDirect) | Separate pricing | From $299/month |
Complete tirzepatide dosing schedule
Tirzepatide is available in pre-filled, single-dose injector pens as well as the newer KwikPen format (FDA-approved in late 2024), which consolidates four weekly doses into a single device for added convenience. All formulations come in the same six dose strengths:
- 2.5 mg / 0.5 mL
- 5 mg / 0.5 mL
- 7.5 mg / 0.5 mL
- 10 mg / 0.5 mL
- 12.5 mg / 0.5 mL
- 15 mg / 0.5 mL
Starting dose for tirzepatide
Per the current FDA-approved prescribing information, all patients begin tirzepatide at 2.5 mg once weekly, regardless of indication. This starting dose is strictly for initiation – it is not an approved maintenance dose and is not associated with significant therapeutic effect on its own. Its purpose is to prime the body and minimize early gastrointestinal side effects before escalation begins.
The max dose of tirzepatide
The tirzepatide max dose is 15 mg. However, each individual’s max dose will vary. The maximum maintenance dose for each patient will be determined by their healthcare provider. Your healthcare provider will consider your side effects and progress when determining your maintenance dose.
Maintenance dose of tirzepatide
The maintenance dose – the dose a patient stays on long-term – varies by individual. The FDA identifies 5 mg, 10 mg, and 15 mg as the approved maintenance doses. The 15 mg dose is the maximum. Your provider will determine the appropriate maintenance dose based on how your body responds, your weight loss trajectory, and your side effect profile. Not all patients will need or tolerate the maximum dose.
Tirzepatide titration protocol
After four weeks at the starting dose, the prescribing provider will evaluate tolerability and, if appropriate, increase to 5 mg once weekly. From there, dosage may be increased in 2.5 mg increments after a minimum of four weeks at each level. The FDA-approved dose escalation schedule is outlined in the table below:
| Current Dose | Increase By | Minimum Duration | Next Dose |
| 2.5 mg / 0.5 mL | +2.5 mg | 4 weeks | 5 mg / 0.5 mL |
| 5 mg / 0.5 mL | +2.5 mg | 4 weeks | 7.5 mg / 0.5 mL |
| 7.5 mg / 0.5 mL | +2.5 mg | 4 weeks | 10 mg / 0.5 mL |
| 10 mg / 0.5 mL | +2.5 mg | 4 weeks | 12.5 mg / 0.5 mL |
| 12.5 mg / 0.5 mL | +2.5 mg | 4 weeks | 15 mg / 0.5 mL |
| 15 mg / 0.5 mL | – | Maintenance | Max dose reached |
Some patients may need additional time at a given dose level – for example, if nausea or other gastrointestinal symptoms are still present at the four-week mark. Your provider may elect to hold the current dose for longer before escalating. This is normal and does not indicate treatment failure.
Tirzepatide dosing chart
The tirzepatide dosing schedule is ultimately set by your healthcare provider, but Eli Lilly (the manufacturer of both Mounjaro and Zepbound) has designed a tirzepatide dosing chart that most providers will follow.
If you’re weighing your options beyond tirzepatide alone, it’s worth understanding how it compares to other medications in the GLP-1 class. Semaglutide — the active ingredient in Wegovy and Ozempic — works through a single hormonal pathway and follows a different dosing schedule with a much lower maximum dose of 2.4 mg weekly. For a detailed side-by-side breakdown of how these two medications differ in dosing, efficacy, and suitability, check out Heally’s full guide on tirzepatide vs semaglutide dosage for weight loss.
How to adjust your tirzepatide dose safely?
Knowing when (and how not) to adjust your dose is one of the most important aspects of tirzepatide treatment. Here are the principles guiding safe dose management.
- Never self-adjust. Your tirzepatide dose should only be changed by a licensed healthcare provider. Independent dose adjustments – whether increasing too fast to accelerate results or decreasing to manage symptoms – can compromise both safety and efficacy.
- Track your symptoms between visits. Gastrointestinal side effects such as nausea, vomiting, and constipation are most common during dose escalation. Keeping a brief symptom log helps your provider make informed decisions about your next dose step.
- Communicate changes in your health status. If you start a new medication, develop a kidney or liver condition, or become pregnant, these factors affect how tirzepatide should be dosed and monitored. Tirzepatide is not recommended during pregnancy, and providers typically advise discontinuing the medication at least two months before attempting conception.
- Don’t skip doses – but know what to do if you do. If you miss a weekly injection, take it as soon as possible if it’s within four days of the scheduled day. If more than four days have passed, skip that dose and resume on your regular schedule the following week. Never double up on doses.
What to do if you missed tirzepatide dose?
If you miss your weekly tirzepatide dose, take it as soon as you remember – but only if it’s within four days of your scheduled injection day. If more than four days have passed, skip the missed dose entirely and resume your regular weekly schedule on your next scheduled day. Never take two doses in the same week to make up for a missed one, as this increases the risk of side effects. If you’re unsure what to do, contact your healthcare provider for guidance.
Common side effects during dose escalation
Most tirzepatide side effects are gastrointestinal and occur primarily during dose escalation rather than at steady maintenance doses. They include:
- Nausea and vomiting (most common)
- Decreased appetite
- Constipation or diarrhea
- Heartburn or burping
- Stomach discomfort
These effects tend to diminish as the body adjusts. Eating smaller, lower-fat meals, staying well-hydrated, and avoiding alcohol during dose increases can help manage GI symptoms. Serious side effects – including pancreatitis, gallbladder issues, and acute kidney injury – are rare but require immediate medical attention if suspected.
Frequently Asked Questions
What is the starting dose of tirzepatide?
All patients begin at 2.5 mg once weekly, regardless of whether they’re using it for weight loss or diabetes. This dose is purely an initiation dose – its job is to ease your body into the medication, not to produce therapeutic results.
How often does the dose increase?
Doses are increased in 2.5 mg increments every four weeks at minimum, provided you’re tolerating the current dose well. Your provider may slow the escalation if side effects are still present at the four-week mark.
What is the maximum dose of tirzepatide?
The maximum approved dose is 15 mg once weekly. Not every patient will reach or need this dose – your provider will determine the right maintenance level based on your progress and tolerability.
Do Mounjaro and Zepbound follow the same dosing schedule?
Yes. Both brands contain identical active ingredients and follow the same titration pathway from 2.5 mg up to 15 mg. The difference is in their FDA-approved indications – Mounjaro for type 2 diabetes, Zepbound for weight management and sleep apnea.
Can I speed up the dose escalation on my own?
No. Self-adjusting your dose – in either direction – is not safe and should never be done without your provider’s guidance. Escalating too quickly significantly increases the risk of nausea, vomiting, and other gastrointestinal side effects.
What happens if tirzepatide stops working at my current dose?
Plateaus can happen. Your provider may increase your dose if you haven’t reached the maximum, or review other factors like diet, activity, or medications that could be affecting your response.
Talk to a healthcare Provider to Personalize Your Protocol
No two patients follow exactly the same tirzepatide journey. A 35-year-old with a BMI of 32 and no other conditions will require different monitoring than a 60-year-old managing both obesity and type 2 diabetes with existing insulin therapy. That’s why personalized, provider-guided care matters throughout the entire course of treatment – not just at the initial prescription.
Heally connects patients with licensed medical providers who evaluate medical history, provide personalized dosing recommendations, and monitor treatment progress over time. Through virtual consultations, Heally makes it easy to determine whether tirzepatide is an appropriate option for you, and to get the ongoing support needed to use it safely and effectively.
Sources
- FDA Prescribing Information: Zepbound (tirzepatide) – January 2026 label
- New England Journal of Medicine: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
- AJMC: FDA Approves Monthly KwikPen Option for Tirzepatide
- Drugs.com: Tirzepatide (Zepbound) dosing and safety
- Eli Lilly: Mounjaro Prescribing Information
Medical disclaimer
This article is for educational purposes only and does not constitute medical advice. Only FDA-approved medications have undergone rigorous clinical testing for safety and effectiveness. Always consult with a qualified healthcare provider before starting any medication. Individual results vary significantly.
